Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents

Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost....

Full description

Saved in:
Bibliographic Details
Published in:Journal of health care for the poor and underserved 2017-05, Vol.28 (2), p.621-625
Main Authors: Mattingly II, T. Joseph, Heil, Emily L, Hoke, Kathleen S
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Antiviral drugs
Benzimidazoles - economics
Benzimidazoles - therapeutic use
Budgets
Cost analysis
Cure
Drug Combinations
Drug Costs
Drug Industry - legislation & jurisprudence
Eminent domain
Epidemics
Expenditures
Fair market value
Federal government
Fluorenes - economics
Fluorenes - therapeutic use
Health care access
Hepatitis
Hepatitis C
Hepatitis C - drug therapy
Hepatology
Humans
Imprisonment
Infections
Jurisprudence
Liver
Liver transplantation
Manufacturers
Medicare
Patents as Topic
Patients
Pharmaceuticals
Prescription drugs
Property rights
Public Health
Staggering
Transplantation
Transplants
Uninsured people
United States
Uridine Monophosphate - analogs & derivatives
Uridine Monophosphate - economics
Uridine Monophosphate - therapeutic use
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost. Given the recent attention to these high-priced HCV therapies and the impact treating individuals with HCV is having on drug expenditures in the United States, there may be a need to revisit drug patent laws and the options the federal government has to ensure patient access to care.
ISSN:1049-2089
1548-6869
1548-6869
DOI:10.1353/hpu.2017.0062